|Dr. Alain Baron|
Q: Share with us a brief history of the company. How did your leaders come together? How was the company originally funded?
A: Elcelyx was founded by two former Amylin Pharmaceuticals employees, myself and Martin Brown. Elcelyx was first funded by Morgenthaler Ventures in a Series A round in March of 2010. Currently, the company is funded by Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, and Technology Partners.
Q: Tell me some of your biggest goals for the year.
A: Elcelyx is developing new products to treat metabolic diseases based on a completely novel platform, named “gut sensory modulation,” that shows promise to produce very safe and effective oral therapies.
Q: What are the biggest challenges to achieving these goals?
A: Recognizing the importance of safety of therapeutics for metabolic diseases in the current regulatory environment, Elcelyx has focused its efforts at maximizing safety in its development of novel therapeutics.
Q: If you could change a public policy at the state or federal level, what would it be?
A: Given the time and risks involved with drug development, there is a great need to improve dialogue with the U.S. Food and Drug Administration to make their decisions more predictable.
Q: What is the most rewarding part of your job?
A: The collaborative environment created and nurtured at Elcelyx makes for a very productive and enjoyable workplace. Knowing we are working to address large, unmet medical needs is all the more rewarding.
Q: What are you doing when you’re not at work?
A: I love to spend time with my family and friends, read, play tennis and travel.
CHI-Advancing California biomedical research and innovation